Bowen's Disease (Squamous Cell Carcinoma In Situ) in Immunosuppressed Patients Treated with Imiquimod 5% Cream and a COX Inhibitor, Sulindac: Potential Applications for This Combination of Immunotherapy
- 1 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 27 (2) , 143-146
- https://doi.org/10.1046/j.1524-4725.2001.00199.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cancer Drugs Found to Work in New WayScience, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells11The authors have declared a conflict of interest.Journal of Investigative Dermatology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Overexpression of Thrombospondin-1 Decreases Angiogenesis and Inhibits the Growth of Human Cutaneous Squamous Cell CarcinomasThe American Journal of Pathology, 1999
- Reduced IL-4 and interferon-gamma (IFN-γ) expression by CD4 T cells in patients with chronic lymphocytic leukaemiaClinical and Experimental Immunology, 1999
- Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and ImiquimodCellular Immunology, 1999
- Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463Journal of Investigative Dermatology, 1998
- Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancersBritish Journal of Cancer, 1996
- Interleukin-12: a proinflammatory cytokine with immunoregulatory functionsResearch in Immunology, 1995